Torray Investment Partners LLC Has $1.45 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Torray Investment Partners LLC grew its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 45.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,174 shares of the company’s stock after buying an additional 5,351 shares during the period. Torray Investment Partners LLC’s holdings in Axsome Therapeutics were worth $1,453,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $64,000. KBC Group NV lifted its position in shares of Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after buying an additional 318 shares during the last quarter. Moors & Cabot Inc. bought a new position in shares of Axsome Therapeutics during the third quarter worth approximately $200,000. Finally, Whalen Wealth Management Inc. bought a new position in shares of Axsome Therapeutics during the third quarter worth approximately $236,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Trading Down 0.3 %

Shares of AXSM stock opened at $127.15 on Tuesday. The stock’s fifty day moving average price is $105.81 and its two-hundred day moving average price is $96.81. The company has a market cap of $6.20 billion, a PE ratio of -21.23 and a beta of 1.05. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. Equities analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 22.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company increased their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Morgan Stanley increased their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Leerink Partners increased their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Finally, Truist Financial increased their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $167.36.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.